CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 176 enrolled
Drug / intervention
Esmolol Hydrochloride +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03998436
NCT03998436Phase 3Completed

A Prospective, Multicenter, Randomized, Double-Blind, Phase 3 Study to Evaluate the Safety and Efficacy of a Gel Formulation of Esmolol Hydrochloride (Galnobax®) in Treating Diabetic Foot Ulcers

Novalead Pharma Private Limited·interventional·Posted Jun 26, 2019·Updated Sep 22, 2023

In Brief

A Phase 3 clinical trial evaluating Esmolol Hydrochloride, Only Standard of Care, and 1 other intervention for Diabetic Foot Ulcer. Completed, enrolled 176 participants across 14 sites.

Detailed Summary

The purpose of the current Study is to determine the safety and effectiveness of Galnobax® plus Standard of Care versus only Standard of Care, in treating Diabetic Foot Ulcers (DFU). In addition, Study is designed to investigate the safety of Galnobax® vehicle for establishing non-deleterious effects of Vehicle on wound healing in the Subjects with DFU. The study is being conducted in 350 subjects being recruited in about 30 centers in India.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesIndia
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJun 26, 2019
Enrollment StartDec 26, 2018
Primary CompletionAug 19, 2021
Study CompletionDec 6, 2021
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 7.0 years ago

Interventions

Esmolol Hydrochloridedrug

Galnobax-14% gel application along with Standard of Care

Only Standard of Careother

Only Standard of Care treatment

Vehicle Gelother

Vehicle gel application along with Standard of Care